Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Non-Current Debt (2021 - 2024)

Inmune Bio's Non-Current Debt history spans 4 years, with the latest figure at $2.5 million for Q3 2024.

  • For Q3 2024, Non-Current Debt rose 5.22% year-over-year to $2.5 million; the TTM value through Sep 2024 reached $2.5 million, up 5.22%, while the annual FY2022 figure was $9.7 million, 32.93% down from the prior year.
  • Non-Current Debt for Q3 2024 was $2.5 million at Inmune Bio, down from $5.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $14.6 million in Q2 2022 and bottomed at $2.4 million in Q3 2023.
  • The 4-year median for Non-Current Debt is $9.7 million (2022), against an average of $9.5 million.
  • The largest annual shift saw Non-Current Debt plummeted 80.41% in 2023 before it increased 5.22% in 2024.
  • A 4-year view of Non-Current Debt shows it stood at $14.5 million in 2021, then crashed by 32.93% to $9.7 million in 2022, then plummeted by 75.5% to $2.4 million in 2023, then increased by 5.22% to $2.5 million in 2024.
  • Per Business Quant, the three most recent readings for INMB's Non-Current Debt are $2.5 million (Q3 2024), $5.0 million (Q2 2024), and $7.5 million (Q1 2024).